Comparative Pharmacology
Head-to-head clinical analysis: TETRACHEL versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETRACHEL versus TETREX.
TETRACHEL vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic